Telix Pharmaceuticals announces shareholder meeting

Bitget2026/09/21 01:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Telix Pharmaceuticals will hold an extraordinary general meeting in November 2026.
Shareholders will vote on the proposed merger to acquire ITM Isotope Technologies Munich for upfront consideration of USD 1.65 billion.
The deal includes payment of about USD 1.25 billion in Telix shares, assumption of USD 302 million net debt, closing adjustments.
Meeting agenda also covers potential contingent consideration of up to USD 700 million tied to FDA approvals and ITM-11 sales milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609202154PR_NEWS_EURO_ND__EN52258) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.

华尔街见闻•2026/10/15 13:26